附件

世界反兴奋剂条例
国际标准
禁用清单
2027年

《禁用清单》的正式文本由世界反兴奋剂机构负责保存，并以英文和法文公布。如英文文本与与法文文本或中文文本之间存在任何冲突，应以英文文本为准。

本清单自2027年1月1日起生效

TABLE OF CONTENTS

目录

Please note that the list of examples of medical conditions below is not inclusive.
请注意，以下所列病症仅为举例。

SUBSTANCES & METHODS PROHIBITED AT ALL TIMES
所有场合禁用的物质和方法

S0 Non-approved substances 7
未获批准的物质

S1 Anabolic agents 8
蛋白同化制剂
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism.
本类别某些物质可能存在但不限于治疗如男性性腺功能减退症等疾病的药物中。

S2 Peptide hormones, growth factors, related substances, and mimetics..... 12
肽类激素、生长因子、相关物质和模拟物
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency.
本类别某些物质可能存在但不限于治疗如贫血、男性性腺功能减退症、生长激素缺乏症等疾病的药物中。

S3 Beta-2 agonists 15
β_2激动剂
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders.
本类别某些物质可能存在但不限于治疗如哮喘和其他呼吸系统疾病的药物中。

S4 Hormone and metabolic modulators 17
激素及代谢调节剂
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility(female), polycystic ovarian syndrome.
本类别某些物质可能存在但不限于治疗如乳腺癌、糖尿病、不孕症(女性)、多囊卵巢综合征等疾病的药物中。

S5 Diuretics and masking agents 20
利尿剂和掩蔽剂
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.
本类别某些物质可能存在但不限于治疗如心力衰竭、高血压等疾病的药物中。

M1 - M2 - M3 Prohibited ethods.....22
禁用方法

SUBSTANCES & METHODS PROHIBITED IN-COMPETITION
赛内禁用的物质和方法

S6 Stimulants 24
刺激剂
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders(ADHD), cold and influenza symptoms.
本类别某些物质可能存在但不限于治疗如过敏反应、注意缺陷多动障碍（ADHD）、感冒和流感症状等疾病的药物中。

S7 Narcotics 30
麻醉剂
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries.
本类别某些物质可能存在但不限于治疗如疼痛（包括肌肉骨骼损伤）等疾病的药物中。

S8 Cannabinoids 31
大麻（酚）类

S9 Glucocorticoids 32
糖皮质激素
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease.
本类别某些物质可能存在但不限于治疗如过敏、过敏反应、哮喘、炎性肠病等疾病的药物中。

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS
特殊项目禁用的物质

P1 Beta-blockers 34
β -阻断剂
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.

本类别某些物质可能存在但不限于治疗如心力衰竭、高血压等疾病的药物中。

附：

The 2027 Monitoring Program..... 36
2027年监控程序

Summary of Major Modifications And Explanatory Notes
2027 Prohibited List..... 38
2027年《禁用清单》主要修订及注释概要

THE 2027 PROHIBITED LIST

2027 年《禁用清单》

WORLD ANTI-DOPING CODE

《世界反兴奋剂条例》

VALID 1 JANUARY 2027

2027 年 1 月 1 日起生效

Introduction
导言

The *Prohibited List* is a mandatory *International Standard* as part of the World Anti-Doping Program.

《禁用清单》是强制性的国际标准，是世界反兴奋剂体系的组成部分。

The *List* is updated annually following an extensive consultation process facilitated by *WADA*. The effective date of the *List* is 01 January 2027.

《禁用清单》由世界反兴奋剂机构（以下简称“WADA”）在广泛征求意见后发布，每年更新一次。本《禁用清单》自2027年1月1日起生效。

The official text of the *Prohibited List* shall be maintained by *WADA* and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

《禁用清单》的正式文本由WADA负责保存，并以英文和法文公布。如英文文本与法文文本之间存在任何冲突，应当以英文文本为准。

Below are some terms used in this *List* of *Prohibited Substances* and *Prohibited Methods*.

以下是本《禁用清单》中使用的一些术语。

Prohibited In-Competition
赛内禁用

Subject to a different period having been approved by *WADA* for a given sport, the *In-Competition* period shall in principle be the period commencing just before midnight(at 11:59 p.m.) on the day before a *Competition* in which the *Athlete* is scheduled to participate until the end of the *Competition* and the *Sample* collection process.

赛内原则上是指从运动员参赛的前一天晚11:59开始，直至该比赛和与之相关的样本采集程序结束为止的时间段，除非WADA为某一特定运动项目批准了不同的时间段。

Prohibited at all times
所有场合禁用

This means that the substance or method is prohibited *In-* and

Out-of-Competition as defined in the *Code*.

即该物质或方法在《条例》定义的赛内和赛外均禁用。

Specified and non-*Specified*
特定和非特定

As per Article 4.2.2 of the *World Anti-Doping Code*, "for purposes of the application of Article 10, all *Prohibited Substances* shall be *Specified Substances* except as identified on the *Prohibited List*. No *Prohibited Method* shall be a *Specified Method* unless it is specifically identified as a *Specified Method* on the *Prohibited List*". As further stated in the article, "the *Specified Substances* and *Methods* identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an *Athlete* for a purpose other than the enhancement of sport performance."

依照《条例》第4.2.2条，"为适用第10条，除《禁用清单》中明确列出的物质外，所有禁用物质均属于特定物质。除非在《禁用清单》中明确列出为特定方法，任何禁用方法均不属于特定方法"。该条进一步规定，"第4.2.2条所指的特定物质和特定方法绝不能视为没有其他兴奋剂物质或方法重要或危险。相反，这些物质和方法更有可能被运动员摄入或使用，用于提高运动能力以外的其他目的。"

Substances of Abuse
滥用物质

Pursuant to Article 4.2.3 of the Code, *Substances of Abuse* are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated *Substances of Abuse*: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/"ecstasy"), tetrahydrocannabinol (THC) or their metabolites, if their presence is consistent with the Use of *a Substance of Abuse*.

依照《条例》第4.2.3条，滥用物质指在体育运动之外的社会环境中更常被滥用的物质。下列物质被指定为滥用物质：可卡因，二醋吗啡（海洛因），*N*-甲基亚甲二氧基苯丙胺[MDMA/亚甲二氧甲基苯丙胺(中文注:摇头丸主要成分)]，四氢大麻酚(THC)或它们的代谢物(如果代谢物的存在与滥用物质的使用相符)。

S0. NON-APPROVED SUBSTANCES

未获批准的物质

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)
所有场合禁用（赛内和赛外）
All prohibited substances in this class are *Specified Substances*.
本类别中所有禁用物质均为特定物质。

Any pharmacological substance which is not addressed by any of the subsequent sections of the *List* and with no current approval by any governmental regulatory health authority for human therapeutic use(e.g.drugs under pre-clinical or clinical development or discontinued, designer drugs, peptides, substances approved only for veterinary use)is prohibited at all times.

本《禁用清单》以下各节未涉及且目前尚未获得任何政府健康管理部门批准用于人体治疗的任何药理学物质（例如：处于临床前或临床开发中或已终止临床试验的药物、设计药物、肽类物质、仅获批用于兽用的物质），在所有场合都禁用。

This class covers many different substances including but not limited to BPC-157, 2,4-dinitrophenol(DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv).

本类别涵盖许多不同的物质,包括但不限于BPC-157、2,4-二硝基苯酚(DNP)、兰尼碱受体-1-钙稳定蛋白复合物稳定剂(阿诺碱受体-1-钙稳定蛋白复合物稳定剂)[例如：S-107和S48168（ARM210）] 和肌钙蛋白激活剂（例如：瑞地生替和泰拉生替）。

S1.ANABOLIC AGENTS

蛋白同化制剂

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)
所有场合禁用（赛内和赛外）
All prohibited substances in this class are non-*Specified Substances*.
本类别中所有禁用物质均为非特定物质。

Anabolic agents are prohibited.
蛋白同化制剂禁用。

S1.1.ANABOLIC ANDROGENIC STEROIDS(AAS)
蛋白同化雄性类固醇（AAS）

When administered exogenously,including but not limited to:
外源性摄入时禁用，包括但不限于：
1-Androstenediol(5α -androst-1-ene-3β ,17β -diol);
1-雄烯二醇（5α -雄甾-1-烯-3β ，17β -二醇）
1-Androstenedione(5α -androst-1-ene-3,17-dione);
1-雄烯二酮（5α -雄甾-1-烯-3，17-二酮）
1-Androsterone(3α -hydroxy-5α -androst-1-ene-17-one);
1-雄酮（3α -羟基-5α -雄甾-1-烯-17-酮）
1-Epiandrosterone(3β -hydroxy-5α -androst-1-ene-17-one);
1-表雄酮（3β -羟基-5α -雄甾-1-烯-17-酮）
1-Testosterone(17β -hydroxy-5α -androst-1-en-3-one);
1-睾酮（17β -羟基-5α -雄甾-1-烯-3-酮）
4-Androstenediol(androst-4-ene-3β ,17β -diol);
4-雄烯二醇（雄甾-4-烯-3β ，17β -二醇）
4-Hydroxytestosterone(4,17β -dihydroxyandrost-4-en-3-one);
4-羟基睾酮（4，17β -二羟基雄甾-4-烯-3-酮）
5-Androstenedione(androst-5-ene-3,17-dione);
5-雄烯二酮（雄甾-5-烯-3，17-二酮）
7α -Hydroxy-DHEA;
7α -羟基-普拉睾酮
7β -Hydroxy-DHEA;
7β -羟基-普拉睾酮
7-Keto-DHEA;
7-羰基-普拉睾酮
11β -Methyl-19-nortestosterone;
11β -甲基-19-去甲睾酮
17α -Methylepithiostanol(epistane);
甲基环硫雄醇（epistane）
19-Norandrostenediol(estr-4-ene-3,17-diol);

19-去甲雄烯二醇（雌甾-4-烯-3，17-二醇）
19-Norandrostenedione(estr-4-ene-3,17-dione);
19-去甲雄烯二酮（雌甾-4-烯-3，17-二酮）
Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone);
雄甾-4-烯-3，11，17-三酮 (11-羰基-4-雄烯二酮，肾上腺雄甾酮)
Androstanolone(5α -dihydrotestosterone,17β -hydroxy-5α -androstan-3-one);
雄诺龙（5α -双氢睾酮, 17β -羟基-5α -雄烷-3-酮）
Androstenediol(androst-5-ene-3β ,17β -diol);
5-雄烯二醇（雄甾-5-烯-3β ， 17β -二醇）
Androstenedione(androst-4-ene-3,17-dione);
4-雄烯二酮（雄甾-4-烯-3，17-二酮）
Bolasterone;
勃拉睾酮
Boldenone;
勃地酮
Boldione(androsta-1,4-diene-3,17-dione);
1,4-雄烯二酮（雄甾-1，4-二烯-3，17-二酮）
Calusterone;
卡芦睾酮
Clostebol;
氯司替勃
Danazol([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α -ol);
达那唑（ [1，2]噁唑[4'，5'：2，3]孕甾-4-烯-20-炔-17α -醇）
Dehydrochlormethyltestosterone(4-chloro-17β -hydroxy-17α -methylandrosta-1,4-dien-3-one);
去氢氯甲睾酮（脱氢氯甲睾酮，4-氯-17β -羟基-17α -甲基雄甾-1，4-二烯-3-酮）
Desoxymethyltestosterone(17α -methyl-5α -androst-2-en-17β -ol and 17α -methyl-5α -androst-3-en-17β -ol);
去氧甲睾酮（17α -甲基-5α -雄甾-2-烯-17β -醇和17α -甲基-5α -雄甾-3-烯-17β -醇）
Dimethandrolone (7α ,11β -Dimethyl-19-nortestosterone);
二甲基诺龙 (7α ，11β -二甲基-19-去甲睾酮)
Drostanolone;
屈他雄酮
Epiandrosterone(3β -hydroxy-5α -androstan-17-one);
表雄酮（3β -羟基-5α -雄烷-17-酮）
Epi-dihydrotestosterone(17β -hydroxy-5β -androstan-3-one);
表双氢睾酮（17β -羟基-5β -雄烷-3-酮）
Epitestosterone;
表睾酮
Ethylestrenol(19-norpregna-4-en-17α -ol);
乙雌烯醇（19-去甲孕-4-烯-17α -醇）

Fluoxymesterone;
氟甲睾酮
Formebolone;
甲酰勃龙
Furazabol(17α -methyl[1,2,5]oxadiazolo[3',4':2,3]-5α -androstan-17β -ol);
夫拉扎勃（17α -甲基[1,2,5]噁二唑[3',4':2,3]-5α -雄烷-17β -醇）
Gestrinone;
孕三烯酮
Mestanolone;
美雄诺龙
Mesterolone;
美睾酮
Metandienone(17β -hydroxy-17α -methylandrosta-1,4-dien-3-one);
美雄酮（17β -羟基-17α -甲基雄甾-1,4-二烯-3-酮）
Metenolone;
美替诺龙
Methandriol;
美雄醇
Methasterone(17β -hydroxy-2α ,17α -dimethyl-5α -androstan-3-one);
甲基屈他雄酮（17β -羟基-2α ,17α -二甲基-5α -雄烷-3-酮）
Methyl-1-testosterone (17β -hydroxy-17α -methyl-5α -androst-1-en-3-one);
甲基-1-睾酮（17β -羟基-17α -甲基-5α -雄甾-1-烯-3-酮）
Methylclostebol;
甲基氯司替勃
Methyldienolone(17β -hydroxy-17α -methylestra-4,9-dien-3-one);
甲二烯诺龙（17β -羟基-17α -甲基雌甾-4,9-二烯-3-酮）
Methylnortestosterone(17β -hydroxy-17α -methylestr-4-en-3-one);
甲诺睾酮（17β -羟基-17α -甲基雌甾-4-烯-3-酮）
Methyltestosterone;
甲睾酮
Metribolone(methyltrienolone,17β -hydroxy-17α -methylestra-4,9,11-trien-3-one);
美曲勃龙（甲基群勃龙,17β -羟基-17α -甲基雌甾-4,9,11-三烯-3-酮）
Mibolerone;
米勃酮
Nandrolone(19-nortestosterone);
诺龙（19-去甲睾酮）
Norboletone;
诺勃酮
Norclostebol(4-chloro-17β -ol-estr-4-en-3-one);
诺司替勃（4-氯-17β -醇-雌甾-4-烯-3-酮）
Norethandrolone;
诺乙雄龙

Oxabolone;
羟勃龙
Oxandrolone;
氧雄龙
Oxymesterone;
羟甲睾酮
Oxymetholone;
羟甲烯龙
Prasterone(dehydroepiandrosterone,DHEA, 3β -hydroxyandrost-5-en-17-one);
普拉睾酮（脱氢表雄酮，DHEA，3β -羟基雄甾-5-烯-17-酮）
Prostanozol(17β -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α -androstane);
前列他唑（17β -[（四氢吡喃-2-基）氧]-1'氢-吡唑[3,4:2,3]-5α -雄烷）
Quinbolone;
奎勃龙
Stanozolol;
司坦唑醇
Stenbolone;
司腾勃龙
Testosterone;
睾酮
Tetrahydrogestrinone(17-hydroxy-18a-homo-19-nor-17α -pregna-4,9,11-trien-3-one);
四氢孕三烯酮（17-羟基-18a-增-19-去甲基-17α -孕甾-4,9,11-三烯-3-酮）
Tibolone;
替勃龙
Trenbolone(17β -hydroxyestr-4,9,11-trien-3-one);
群勃龙（17β -羟基雌甾-4,9,11-三烯-3-酮）
Trestolone(7α -Methyl-19-nortestosterone,MENT);
曲托龙（7α -甲基-19-去甲睾酮, MENT）
and other substances with a similar chemical structure or similar biological effect(s) including their esters.
以及其他具有类似化学结构或类似生物效应的物质,包括其酯类物质。

S1.2.OTHER ANABOLIC AGENTS
其他蛋白同化制剂
Including, but not limited to:
包括但不限于：
Clenbuterol,osilodrostat, ractopamine, selective androgen receptor modulators[SARMs, e.g.andarine, enobosarm(ostarine), LGD-4033(ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol.
克仑特罗、奥唑司他、雷托巴胺、选择性雄激素受体调节剂[SARMs，例如：andarine、依诺波沙（ostarine）、LGD-4033（ligandrol）、RAD140、S-23和YK-11]、泽仑诺和齐帕特罗。

S2. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS

肽类激素、生长因子、相关物质和模拟物

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

所有场合禁用（赛内和赛外）

All prohibited substances in this class are non-*Specified Substances*.

本类别中所有禁用物质均为非特定物质。

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited.

下列物质以及其他具有类似化学结构或类似生物效应的物质，均禁用。

S2.1. ERYTHROPOIETINS(EPO) AND AGENTS AFFECTING ERYTHROPOIESIS

促红素类（EPO）以及影响红细胞生成的制剂

Including, but not limited to:

包括但不限于：

S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins(dEPO); erythropoietins(EPO); EPO-based constructs[e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta(CERA)]; EPO-mimetic agents and their constructs(e.g. CNTO-530, peginesatide, pegmolesatide).

促红素受体激动剂类，例如：达促红素类（dEPO）；促红素类（EPO）；基于促红素类分子结构的构建物[例如：促红素融合蛋白（EPO-Fc）、培促红素β（CERA）]；促红素模拟物及其构建物（例如：CNTO-530、培尼沙肽、培莫沙肽）。

S2.1.2 Hypoxia-inducible factor(HIF) activating agents, e.g. cobalt; daprodustat(GSK1278863); IOX2; molidustat(BAY 85-3934); roxadustat(FG-4592); vadadustat(AKB-6548); xenon.

缺氧诱导因子(HIF)激活剂类，例如：钴化合物；达普司他(GSK1278863)；特异性的脯氨酰羟化酶-2(PHD2)抑制剂(IOX2)；莫立司他(BAY 85-3934)；罗沙司他（FG-4592）；伐达度司他（AKB-6548）；氙气。

S2.1.3 GATA inhibitors, e.g. K-11706.

GATA抑制剂，例如：K-11706。

S2.1.4 Transforming growth factor beta(TGF-β) signalling inhibitors, e.g. luspatercept; sotatercept.

转化生长因子-β（TGF-β）信号传导抑制剂，例如：罗特西普；索特西普。

S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO).

先天修复受体激动剂类，例如：唾液酸促红素；氨甲酰促红素（CEPO）。

S2.2.PEPTIDE HORMONES AND THEIR RELEASING FACTORS
肽类激素及其释放因子

S2.2.1 Testosterone-stimulating peptides in males including, but not limited to:
睾酮刺激肽（男性禁用），包括但不限于：
•chorionic gonadotrophin(CG),
•绒促性素（CG）
•luteinizing hormone(LH),
•促黄体生成素（LH）
•gonadotrophin-releasing hormone(GnRH, gonadorelin) and its agonist analogues(e.g.buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin),
•促性腺激素释放激素（GnRH，戈那瑞林）及其激动剂类似物（例如：布舍瑞林、地洛瑞林、戈舍瑞林、组氨瑞林、亮丙瑞林、那法瑞林和曲普瑞林），
•kisspeptin and its agonist analogues.
•Kisspeptin及其激动剂类似物。

S2.2.2 Corticotrophins and their releasing factors, e.g.corticorelin and tetracosactide.
促皮质素类及其释放因子，例如：可的瑞林和替可克肽。

S2.2.3 Growth hormone(GH),its analogues and fragments including, but not limited to:
生长激素（GH）及其类似物和片段，包括但不限于：
•growth hormone analogues, e.g.lonapegsomatropin, somapacitan and somatrogon;
生长激素类似物，例如：隆培促生长素、帕西生长素和曲更生长素；
•growth hormone fragments,e.g.AOD-9604 and hGH 176-191.
生长激素片段，例如：AOD-9604和人生长激素176-191（hGH 176-191）。

S2.2.4 Growth hormone releasing factors, including,but not limited to:
生长激素释放因子，包括但不限于：
•growth hormone-releasing hormone(GHRH) and its analogues (e.g.CJC-1293,CJC-1295,sermorelin and tesamorelin);
•生长激素释放激素（GHRH）及其类似物（例如：CJC-1293、CJC-1295、舍莫瑞林和替莫瑞林）；
•growth hormone secretagogues(GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin];
•生长激素促分泌剂类（GHS）及其模拟物 [例如：阿那瑞林、卡莫瑞林、伊布莫仑（MK-677） 、伊帕瑞林、来诺瑞林（葛瑞林/脑肠肽）、马昔瑞林和他莫瑞林]；
•GH-releasing peptides(GHRPs)[e.g.alexamorelin, examorelin (hexarelin),GHRP-1,GHRP-2(pralmorelin),GHRP-3,GHRP-4,GHRP-5

and GHRP-6].

•生长激素释放肽类（GHRPs），[例如：艾瑞莫瑞林、艾莫瑞林（海沙瑞林）、生长激素释放肽-1（GHRP-1）、生长激素释放肽-2（普拉莫瑞林）、生长激素释放肽-3（GHRP-3）、生长激素释放肽-4（GHRP-4）、生长激素释放肽-5（GHRP-5）和生长激素释放肽-6（GHRP-6）]。

S2.3.GROWTH FACTORS AND GROWTH FACTOR MODULATORS

生长因子以及生长因子调节剂

Including, but not limited to:

包括但不限于：

Fibroblast growth factors(FGFs);

成纤维细胞生长因子类（FGFs）

Hepatocyte growth factor(HGF);

肝细胞生长因子（HGF）

Insulin-like growth factor 1(IGF-1, mecasermin) and its analogues;

胰岛素样生长因子1（IGF-1，美卡舍明）及其类似物

Mechano growth factors(MGFs);

机械生长因子类（MGFs）

Platelet-derived growth factor(PDGF);

血小板衍生生长因子（PDGF）

Thymosin-β 4 and its derivatives e.g.TB-500;

胸腺肽-β 4及其衍生物，例如：TB-500

Vascular endothelial growth factor(VEGF);

血管内皮生长因子（VEGF）

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

以及其他影响肌肉、肌腱或韧带蛋白质合成/分解、血管形成、能量利用、再生能力或纤维类型转换的生长因子或生长因子调节剂。

S3.BETA-2 AGONISTS

β 2激动剂

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)
所有场合禁用（赛内和赛外）
All prohibited substances in this class are *Specified Substances*.
本类别中所有禁用物质均为特定物质。

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.
所有选择性和非选择性β 2激动剂，包括所有光学异构体，均禁用。
Including, but not limited to:
包括但不限于：

Arformoterol;
阿福特罗
Fenoterol;
非诺特罗
Formoterol;
福莫特罗
Higenamine;
去甲乌药碱
Indacaterol;
茚达特罗
Levosalbutamol;
左沙丁胺醇
Olodaterol;
奥达特罗
Procaterol;
丙卡特罗
Reproterol;
瑞普特罗
Salbutamol;
沙丁胺醇
Salmeterol;
沙美特罗
Terbutaline;
特布他林
Tretoquinol(trimetoquinol);
曲托喹酚（trimetoquinol）
Tulobuterol;
妥洛特罗

Vilanterol;
维兰特罗

EXCEPTIONS
例外

- Inhaled salbutamol:maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose;
  吸入使用沙丁胺醇（salbutamol）：24小时内最多不超过1600微克，任意8小时不超过600微克；
- Inhaled formoterol:maximum delivered dose of 54 micrograms over 24 hours in divided doses not to exceed 36 micrograms over 12 hours starting from any dose;
  吸入使用福莫特罗（formoterol）：24小时内最多不超过54微克，任意12小时不超过36微克；
- Inhaled salmeterol:maximum 200 micrograms over 24 hours in divided doses not to exceed 100 micrograms over 8 hours starting from any dose;
  吸入使用沙美特罗（salmeterol）：24小时内最多不超过200微克，任意8小时不超过100微克；
- Inhaled vilanterol:maximum 25 micrograms over 24 hours.
  吸入使用维兰特罗（vilanterol）：24小时内最多不超过25微克。

NOTE
注意

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an *Adverse Analytical Finding(AAF)* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose(by inhalation) up to the maximum dose indicated above.
若尿液中沙丁胺醇浓度超过1000ng/ml，或福莫特罗浓度超过40ng/ml，不符合该物质的治疗用途，将被视为阳性检测结果（AAF）。除非运动员通过受控的药代动力学研究，证明该异常结果是由于治疗性吸入上述最大剂量药物所致。

S4.HORMONE AND METABOLIC MODULATORS

激素及代谢调节剂

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

所有场合禁用（赛内和赛外）

Prohibited substances in classes S4.1 and S4.2 are *Specified Substances*. Those in classes S4.3 and S4.4 are non-*Specified Substances*.

S4.1和S4.2中的禁用物质为特定物质。S4.3和S4.4中的禁用物质为非特定物质。

The following hormone and metabolic modulators are prohibited:

下列激素和代谢调节剂禁用：

S4.1.AROMATASE INHIBITORS

芳香酶抑制剂

Including, but not limited to:

包括但不限于：

2-Androstenol(5α -androst-2-en-17-ol);

2-雄烯醇（5α -雄甾-2-烯-17-醇）

2-Androstenone(5α -androst-2-en-17-one);

2-雄烯酮（5α -雄甾-2-烯-17-酮）

2-Phenylbenzo[h]chromen-4-one (α -naphthoflavone; 7,8-benzoflavone);

2-苯基苯并[h]色烯-4-酮（α -萘黄酮；7,8-苯并黄酮）

3-Androstenol(5α -androst-3-en-17-ol);

3-雄烯醇（5α -雄甾-3-烯-17-醇）

3-Androstenone(5α -androst-3-en-17-one);

3-雄烯酮（5α -雄甾-3-烯-17-酮）

4-Androstene-3,6,17 trione(6-oxo);

4-雄烯-3,6,17-三酮（6-氧代）

Aminoglutethimide;

氨鲁米特

Anastrozole;

阿那曲唑

Androsta-1,4,6-triene-3,17-dione(androstatrienedione);

雄甾-1,4,6-三烯-3,17-二酮（雄三烯二酮）

Androsta-3,5-diene-7,17-dione(arimistane);

雄甾-3,5-二烯-7,17-二酮（arimistane）

Exemestane;

依西美坦

Formestane;

福美坦

Letrozole;

来罗唑

Testolactone;
睾内酯

S4.2.ANTI-ESTROGENIC SUBSTANCES[ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS(SERMS) OR DEGRADERS (SERDS)]
抗雌激素作用物质[抗雌激素和选择性雌激素受体调节剂（SERMS）或降解剂（SERDS）]

Including, but not limited to:
包括但不限于：
Bazedoxifene;
巴多昔芬
Clomifene;
氯米芬
Cyclofenil;
环芬尼
Elacestrant;
艾拉司群
Fulvestrant;
氟维司群
Imlunestrant;
依仑司群
Ospemifene;
奥培米芬
Raloxifene;
雷洛昔芬
Tamoxifen;
他莫昔芬
Toremifene;
托瑞米芬

S4.3.AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION
激活素受体IIB活化抑制剂类

Including, but not limited to:
包括但不限于：
•Activin A-neutralizing antibodies;
激活素A中和抗体类
•Activin receptor IIB competitors such as:
激活素受体IIB竞争剂类，例如：
-Decoy activin receptors (e.g.ACE-031);
伪激活素受体类（例如：ACE-031）
•Anti-activin receptor IIB antibodies (e.g.bimagrumab);
激活素受体IIB抗体类（例如：比马鲁人单抗）
•Myostatin inhibitors such as:

肌抑素抑制剂类，例如：

-Agents reducing or ablating myostatin expression;

肌抑素表达消减剂类

-Myostatin-binding proteins (e.g.follistatin, myostatin propeptide);

肌抑素结合蛋白类（例如：卵泡抑素、肌抑素前肽）

-Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagrozumab, landogrozumab, stamulumab);

肌抑素或其前体的中和抗体类（例如：阿匹特古单抗、多古珠单抗、兰度古珠单抗、司他利尤单抗）

S4.4.METABOLIC MODULATORS

代谢调节剂

S4.4.1

- Activators of the AMP-activated protein kinase (AMPK), e.g. 5-*N*,6-*N*-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine (BAM15), AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)
- 腺苷酸活化蛋白激酶(AMPK)激动剂,例如:5-*N*,6-*N*-双(2-氟苯基)-[1,2,5]噁二唑并[3,4-b]吡嗪-5,6-二胺（BAM15）、阿卡地新（AICAR）、基于12S rRNA-c的线粒体开放阅读框（MOTS-c）
- Peroxisome proliferator-activated receptor delta (PPARδ) agonists,e.g.2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid(GW1516,GW501516), seladelpar
- 过氧化物酶体增殖物激活受体δ（PPARδ）激动剂，例如：2-(2-甲基-4-((4-甲基-2-(4-(三氟甲基)苯基)噻唑-5-基)甲硫基)苯氧基)乙酸（GW1516、GW501516）、司拉德帕
- Rev-erbα agonists, e.g. SR9009,SR9011
- Rev-erb核受体激动剂，例如：SR9009、SR9011
- SLU-PP-332, SLU-PP-915 and related substances
- SLU-PP-332、SLU-PP-915和相关物质

S4.4.2 Insulins and insulin-mimetics, e.g. S519, S597

胰岛素类以及胰岛素模拟物类，例如：S519、S597

S4.4.3 Meldonium

美度铵

S4.4.4 Trimetazidine

曲美他嗪

S5. DIURETICS AND MASKING AGENTS

利尿剂和掩蔽剂

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)
所有场合禁用（赛内和赛外）
All prohibited substances in this class are *Specified Substances*.
本类别中所有禁用物质均为特定物质。

All diuretics and masking agents, including all optical isomers, e.g. *d*- and *l*- wherererelevant, are prohibited.
所有利尿剂和掩蔽剂，包括所有光学异构体，例如*d*-型和*l*-型，均禁用。

Including, but not limited to:
包括但不限于：

- Diuretics such as:
  利尿剂，例如：
- Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; eplerenone; etacrynic acid; finerenone; furosemide; indapamide; metolazone; pironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; xipamide
  乙酰唑胺；阿米洛利；布美他尼；坎利酮；氯噻酮；依普利酮；依他尼酸；非奈利酮；呋塞米；吲达帕胺；美托拉宗；螺内酯；噻嗪类，例如：卞氟噻嗪、氯噻嗪和氢氯噻嗪；托拉塞米；氨苯蝶啶；希帕胺
- Vaptans, e.g. conivaptan, mozavaptan, tolvaptan
  伐坦类，例如：考尼伐坦、莫扎伐坦（莫扎伐普坦）、托伐普坦
- Plasma expanders by intravenous administration such as:
  Albumin, dextran, hydroxyethyl starch and mannitol
  静脉输入血容量扩充剂类，例如：
  白蛋白、右旋糖酐、羟乙基淀粉和甘露醇
- Desmopressin
  去氨加压素
- Probenecid
  丙磺舒

and other substances with a similar chemical structure or similar biological effect(s).
以及其他具有类似化学结构或者类似生物效应的物质。

EXCEPTIONS
例外

- Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide)

屈螺酮、巴马溴以及眼科局部用药的碳酸酐酶抑制剂（例如：多佐胺，布林佐胺）
• Local administration of felypressin in dental anaesthesia
牙科局部麻醉中使用的苯赖加压素

NOTE
注意

The detection in an *Athlete's Sample* at all times or *In-Competition*, as applicable,of any quantity of the following substances subject to threshold limits:formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent(except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an *Adverse Analytical Finding(AAF)* unless the *Athlete* has an approved *Therapeutic Use Exemption(TUE)* for that substance in addition to the one granted for the diuretic or masking agent.
如在运动员任何场合或赛内检查的样本中（视情况而定）检测出利尿剂或掩蔽剂（除了碳酸酐酶抑制剂的眼部局部给药，或苯赖加压素在牙科麻醉中的局部给药）的同时，检出任意浓度的以下阈值物质：福莫特罗、沙丁胺醇、去甲伪麻黄碱、麻黄碱、甲基麻黄碱和伪麻黄碱，将视为阳性检测结果（AAF），除非运动员已经获得该阈值物质以及利尿剂或掩蔽剂的治疗用药豁免（TUE）批准。

PROHIBITED METHODS

禁用方法

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

所有场合禁用（赛内和赛外）

All prohibited methods in this class are non-*Specified* except methods in M2.2.which are *Specified Methods*.

除M2.2.中的禁用方法为特定方法外，本类别中所有禁用方法均为非特定方法。

M1.MANIPULATION OF BLOOD AND BLOOD COMPONENTS

篡改血液和血液成分

The following are prohibited:

以下方法禁用：

M1.1. The *Administration* or reintroduction of any quantity of autologous, allogenic(homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

向循环系统中注入或回输任何来源及任何数量的自体、同种异体（同源）或异源血液或血红细胞制品。

The withdrawal of blood or blood components (including by apheresis), unless performed for 1) analytical purposes including medical tests or *Doping Control*, or for 2) donation purposes in a collection center accredited by the relevant regulatory authority of the country in which it operates.

抽取血液或血液成分（包括通过单采技术采集的情况），但以下情况除外：1）用于分析目的，包括医学检查或兴奋剂管制；或 2）在所在国正规的采供血机构，以献血目的进行的献血行为。

M1.2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to:

Perfluorochemicals;efaproxiral(RSR13); voxelotor and modified haemoglobin products,e.g.haemoglobin-based blood substitutes and microencapsulated haemoglobin products,excluding supplemental oxygen by inhalation.

人为提高氧气摄入、输送或运输的方法。包括但不限于：使用全氟化合物；乙丙昔罗（RSR13）；伏塞洛托和经修饰的血红蛋白制剂，例如以血红蛋白为主剂的血液替代品和微囊血红蛋白制剂等，但不包括吸入方式补充氧气。

M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

通过物理或化学手段，以任何形式在血管内篡改血液或血液成分。

M1.4.The use of re-breathing systems or equipment to deliver carbon monoxide, unless performed as a diagnostic procedure under the supervision of a medical or scientific professional.

使用复吸入系统或设备输入一氧化碳，在医疗或科研专业人员的监督下作为诊断程序实施除外。

M2.CHEMICAL AND PHYSICAL MANIPULATION

化学和物理篡改

The following are prohibited:

以下方法禁用：

M2.1.*Tampering*, or *Attempting to Tamper*, to alter the integrity and validity of *Samples* collected during *Doping Control*.

Including, but not limited to:

Sample substitution and/or adulteration, e.g.addition of proteases to *Sample*.

篡改或企图篡改以改变在兴奋剂管制过程中采集到的样本的完整性和有效性。

包括但不限于：

置换样本和/或样本掺假，例如：向样本中添加蛋白酶。

M2.2.Intravenous infusions and/or injections of more than a total of 100mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

每12小时的静脉输液和/或静脉注射量累计超过100ml，但在医院治疗、手术治疗或临床诊断检查过程中正当的使用除外。

M3.GENE AND CELL DOPING

基因和细胞兴奋剂

The following, with the potential to enhance sport performance, are prohibited:

以下具有潜在提高运动能力的方法禁用：

M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies.

使用可能通过任何机制改变基因组序列和/或改变基因表达的核酸或核酸类似物，包括但不限于基因编辑、基因沉默和基因转移技术。

M3.2. The use of normal or genetically modified cells or cell components (e.g. nuclei and organelles such as mitochondria and ribosomes).

使用常规细胞或基因修饰细胞或细胞组分（例如：细胞核以及线粒体、核糖体等细胞器）。

S6.STIMULANTS

刺激剂

PROHIBITED IN-COMPETITION

赛内禁用

All prohibited substances in this class are *Specified Substances* except those in S6.A, which are non-*Specified Substances*.

除S6.A中的禁用物质为非特定物质外，本类别中的所有其他禁用物质均为特定物质。

Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine(MDMA/“ecstasy”)

本节内的滥用物质：可卡因和*N*-甲基亚甲二氧基苯丙胺[MDMA/“亚甲基二氧甲基苯丙胺”(中文注：摇头丸主要成分)]。

All stimulants, including all optical isomers, e.g. *d*-and *l*-where relevant, are prohibited.

所有刺激剂，包括所有光学异构体（例如*d*-型和*l*-型）均禁用。

Stimulants include:

刺激剂包括：

S6.A:NON-SPECIFIED STIMULANTS

非特定刺激剂：

Adrafinil;

阿屈非尼

Amfepramone;

安非拉酮

Amfetamine;

苯丙胺

Amfetaminil;

安非他尼

Amiphenazole;

阿米苯唑

Benfluorex;

苯氟雷司

Benzylpiperazine;

苄基哌嗪

Bromantan;

布罗曼坦

Clobenzorex;

氯苄雷司

Cocaine;

可卡因
Cropropamide;
克罗丙胺
Crotetamide;
克罗乙胺
Fencamine;
芬咖明
Fenetylline;
芬乙茶碱
Fenfluramine;
芬氟拉明
Fenproporex;
芬普雷司
Fladrafinil(2-[Bis(4-fluorophenyl)methylsulfinyl]-N-hydroxyacetamide);
氟阿屈非尼（2-[双(4-氟苯基)甲基亚硫酰基]-N-羟基乙酰胺）
Flmodafinil (2-[Bis(4-fluorophenyl)methylsulfinyl]acetamide);
氟莫达非尼（2-[双(4-氟苯基)甲基亚硫酰基]-乙酰胺）
Fonturacetam[4-phenylpiracetam(carphedon)];
芳妥西坦[4-苯基吡拉西坦（卡非多）]
Furfenorex;
呋芬雷司
Hydrafinil(fluorenol);
羟基芴（芴醇）
Lisdexamfetamine;
利右苯丙胺
Mefenorex;
美芬雷司
Mephentermine;
美芬丁胺
Mesocarb;
美索卡
Metamfetamine(*d*-);
甲基苯丙胺（右旋）
p-methylamfetamine;
对-甲基苯丙胺
Modafinil;
莫达非尼
Norfenfluramine;
去乙芬氟拉明
Phendimetrazine;
苯甲曲秦
Phentermine;
芬特明

Prenylamine;
普尼拉明
Prolintane;
普罗林坦

A stimulant not expressly listed in this section is a *Specified Substance*.
本节未明确列出的刺激剂均为特定物质。

S6.B:SPECIFIED STIMULANTS

特定刺激剂：

Including, but not limited to:
包括但不限于：
2-phenylpropan-1-amine (ß-methylphenylethyl-amine,BMPEA);
2-苯基-1-丙胺（ß-甲基苯乙胺，BMPEA）
3-Methylhexan-2-amine (1,2-dimethylpentylamine);
3-甲基己烷-2-胺（1，2-二甲基戊胺）
4-Fluoromethylphenidate;
4-氟哌醋甲酯
4-Methylhexan-2-amine (1,3-dimethylamylamine,1,3 DMAA, methylhexaneamine);
4-甲基己烷-2-胺（1，3-二甲基戊胺、1，3 DMAA、甲基氨基己烷）
4-Methylpentan-2-amine (1,3-dimethylbutylamine);
4-甲基戊烷-2-胺（1，3-二甲基正丁胺）
5-Methylhexan-2-amine (1,4-dimethylamylamine,1,4-dimethylpentylamine, 1,4-DMAA);
5-甲基己烷-2-胺（1，4-二甲基戊胺、1，4-DMAA）
Benzfetamine;
苄非他明
Cathine**;
去甲伪麻黄碱**
Cathinone and its analogues, e.g.mephedrone, methedrone, and α -pyrrolidinovalerophenone;
卡西酮及其同系物（例如：4-甲基甲卡西酮、4-甲氧基甲卡西酮、α -吡咯烷基苯戊酮）
Dimetamfetamine(dimethylamphetamine);
二甲基苯丙胺（dimethylamphetamine）
Ephedrine***;
麻黄碱***
Epinephrine****(adrenaline);
肾上腺素****（adrenaline）
Etamivan;
香草二乙胺
Ethylphenidate;

哌醋乙酯
Etilamfetamine;
乙非他明
Etilefrine;
依替福林
Famprofazone;
泛普法宗
Fenbutrazate;
芬布酯
Fencamfamin;
芬坎法明
Heptaminol;
辛胺醇
Hydroxyamfetamine(parahydroxyamphetamine);
羟苯丙胺（对-羟基苯丙胺）
Isometheptene;
异美汀
Levmetamfetamine;
左去氧麻黄碱
Meclofenoxate;
甲氯芬酯
Methylenedioxymethamphetamine;
N-甲基亚甲二氧基苯丙胺
Methylephedrine***;
甲基麻黄碱***
Methylnaphthidate[(±)-methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate];
萘乙酸甲酯[(±)-甲基-2-(萘-2-基)-2-(哌啶-2-基)乙酸酯]
Methylphenidate;
哌甲酯
Midodrine;
米多君
Nikethamide;
尼可刹米
Norfenefrine;
去甲苯福林
Octodrine(1,5-dimethylhexylamine);
奥托君（1，5-二甲基己胺）
Octopamine;
奥克巴胺
Oxilofrine(methylsynephrine);
奥洛福林（甲基辛弗林，又译名：甲昔奈福林）
Pemoline;
匹莫林

Pentetrazol;
戊四氮
Phenethylamine and its derivatives;
苯乙胺及其衍生物
Phenmetrazine;
芬美曲秦
Phenpromethamine;
苯丙甲胺
Propylhexedrine;
丙己君
Pseudoephedrine*****;
伪麻黄碱*****
Selegiline;
司来吉兰
Sibutramine;
西布曲明
Solriamfetol;
索安非托
Strychnine;
士的宁
Tenamfetamine(methylenedioxyamphetamine);
替苯丙胺（亚甲二氧基苯丙胺）
Tesofensine;
替索芬辛
Tuaminoheptane;
异庚胺

and other substances with a similar chemical structure or similar biological effect(s).
以及其他具有类似化学结构或类似生物效应的物质。

EXCEPTIONS
例外
•Clonidine, guanfacine;
可乐定、胍法辛
•Imidazoline derivatives for dermatological,nasal,ophthalmic or otic use(e.g.brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2027 Monitoring Program*.
皮肤、鼻腔、眼科或耳科使用的咪唑啉衍生物（例如：溴莫尼定、氯萘唑啉、非诺唑啉、茚唑啉、萘甲唑啉、羟甲唑啉、四氢唑啉、曲马唑啉、赛洛唑啉）和列入2027年监控程序*的刺激剂。

*Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine,

pipradrol, and synephrine: These substances are included in the 2027 Monitoring Program, and are not considered *Prohibited Substances*.
丁胺苯丙酮、咖啡因、尼古丁、去氧肾上腺素、苯丙醇胺、哌苯甲醇和昔奈福林：被列入2027年监控程序，不属于禁用物质。
**Cathine(d-norpseudoephedrine) and its l-isomer:Prohibited when its concentration in urine is greater than 5 micrograms per millilitre.
去甲伪麻黄碱(d-去甲伪麻黄碱)及其l-异构体：尿中浓度超过5微克/毫升时禁用。
***Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre.
麻黄碱或甲基麻黄碱：任一物质的尿中浓度超过10微克/毫升时禁用。
****Epinephrine(adrenaline):Not prohibited in local administration, e.g. nasal,ophthalmologic,or co-administration with local anaesthetic agents.
肾上腺素(adrenaline)：局部使用（如鼻、眼）或与局部麻醉剂合用时不禁用。
*****Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre.
伪麻黄碱：尿中浓度超过150微克/毫升时禁用。

S7.NARCOTICS

麻醉剂

PROHIBITED IN-COMPETITION

赛内禁用

All prohibited substances in this class are *Specified Substances*.

本类别中所有禁用物质均为特定物质。

Substance of Abuse in this section:diamorphine(heroin)

本节中的滥用物质：二醋吗啡（海洛因）

The following narcotics, including all optical isomers, e.g.*d*- and *l*- where relevant, are prohibited.

下列麻醉剂，包括所有光学异构体，例如*d*-型和*l*-型，均禁用。

Buprenorphine;

丁丙诺啡

Dextromoramide;

右吗拉胺

Diamorphine(heroin);

二醋吗啡（海洛因）

Fentanyl and its derivatives;

芬太尼及其衍生物

Hydromorphone;

氢吗啡酮

Methadone;

美沙酮

Morphine;

吗啡

Nicomorphine;

尼可吗啡

Oxycodone;

羟考酮

Oxymorphone;

羟吗啡酮

Pentazocine;

喷他佐辛

Pethidine;

哌替啶

Tramadol;

曲马多

S8.CANNABINOIDS

大麻（酚）类

PROHIBITED IN-COMPETITION

赛内禁用

All prohibited substances in this class are *Specified Substances*.

本类别中所有禁用物质均为特定物质。

Substance of Abuse in this section:tetrahydrocannabinol(THC)

本节中的滥用物质：四氢大麻酚（THC）。

Tetrahydrocannabinols (THC), as well as semi-synthetic and synthetic cannabinoids that mimic the effects of Δ^{9}-THC, are prohibited, e.g.

四氢大麻酚类（THC），以及模拟Δ^{9}-四氢大麻酚效果的半合成和合成大麻素，均属禁用，例如：

•Δ^{9}-THC as found in cannabis(hashish,marijuana)

大麻成分（大麻脂、大麻）中存在的Δ^{9}-四氢大麻酚（Δ^{9}-THC）

•Δ^{8}-THC and Δ^{10}-THC

Δ^{8}-四氢大麻酚（Δ^{8}-THC）和Δ^{10}-四氢大麻酚（Δ^{10}-THC）

•Hexahydrocannabinols (HHC)

六氢大麻酚类（HHC）

•AB-FUBINACA, 5F-ADB

N-(1-氨甲酰基-2-甲基丙基)-1-(4-氟苄基)吲唑-3-甲酰胺、3,3-二甲基-2-[1-(5-氟戊基)吲唑-3-甲酰氨基]丁酸甲酯

NOTE

注意

•Cannabidiol(CBD) is not prohibited.

大麻二酚（CBD）不禁用。

S9.GLUCOCORTICOIDS

糖皮质激素

PROHIBITED IN-COMPETITION

赛内禁用

All prohibited substances in this class are *Specified Substances*.
本类别中所有禁用物质均为特定物质。

All glucocorticoids are prohibited when administered by any injectable, oral[including oromucosal(e.g.buccal,gingival,sublingual)] or rectal route.
所有糖皮质激素禁止通过任何注射、口服[包括口腔粘膜 (例如：口颊、牙龈、舌下)]或直肠途径给药。

Including, but not limited to:
包括但不限于：
Beclometasone;
倍氯米松
Betamethasone;
倍他米松
Budesonide;
布地奈德
Ciclesonide;
环索奈德
Cortisone;
可的松
Deflazacort;
地夫可特
Dexamethasone;
地塞米松
Flunisolide;
氟尼缩松
Fluocortolone;
氟可龙
Fluticasone;
氟替卡松
Hydrocortisone;
氢化可的松
Methylprednisolone;
甲泼尼龙
Mometasone;
莫米松

Prednisolone;
泼尼松龙
Prednisone;
泼尼松
Triamcinolone acetonide;
曲安奈德

NOTE
注意
Other routes of administration(including inhaled, and topical:dental-intracanal, dermal, intranasal, ophthalmological, otic, perianal and vaginal) are not prohibited when used within the manufacturer's licensed doses and therapeutic indications.
其他给药途径（包括吸入使用和外用:牙科-根管内、皮肤、鼻内、眼科、耳科、肛周和阴道）在药品说明书剂量和治疗适应症范围内不禁用。

P1.BETA-BLOCKERS

β -阻断剂

PROHIBITED IN PARTICULAR SPORTS

特殊运动项目禁用

All prohibited substances in this class are *Specified Substances*.

本类别所有禁用物质均为特定物质。

Beta-blockers are prohibited *In-Competition* only, in the following sports, and also prohibited *Out-of-Competition* where indicated(*).

β -阻断剂仅在下列运动项目的赛内禁用。在标注星号（*）的运动项目的赛外也禁用。

•Archery(WA)*
射箭（WA，国际射箭联合会）*
•Automobile(FIA)
汽车运动（FIA，国际汽车运动联合会）
•Billiards(WCBS)
台球（WCBS，世界台球联盟）
•Darts(WDF)
飞镖（WDF，世界飞镖联合会）
•Golf(IGF)
高尔夫（IGF，国际高尔夫联合会）
•Mini-Golf (WMF)
迷你高尔夫（WMF，世界迷你高尔夫联合会）
•Shooting(ISSF, IPC)*
射击（ISSF，国际射击联合会，IPC，国际残奥委会）*
•Underwater sports(CMAS)* in all subdisciplines of freediving, spearfishing and target shooting
水下运动（CMAS，世界水下运动联合会）*包括自由潜水、水下渔猎和目标射击的所有分项（中文版译注：水下运动各项目暂无通用译名，均为暂译名）。

*Also prohibited *Out-of-Competition*

*赛外也禁用

Including,but not limited to:

包括但不限于：

Acebutolol;

醋丁洛尔

Alprenolol;

阿普洛尔

Atenolol;

阿替洛尔

Betaxolol;

倍他洛尔
Bisoprolol;
比索洛尔
Bunolol;
布诺洛尔
Carteolol;
卡替洛尔
Carvedilol;
卡维地洛
Celiprolol;
塞利洛尔
Esmolol;
艾司洛尔
Labetalol;
拉贝洛尔
Metipranolol;
美替洛尔
Metoprolol;
美托洛尔
Nadolol;
纳多洛尔
Nebivolol;
奈必洛尔
Oxprenolol;
氧烯洛尔
Pindolol;
吲哚洛尔
Propranolol;
普萘洛尔
Sotalol;
索他洛尔
Timolol.
噻吗洛尔

The 2027 Monitoring Program*
2027年监控程序*

The following substances are placed on the 2027 Monitoring Program:
以下物质列入2027年监控程序：

1.Anabolic Agents:
蛋白同化制剂：
In and *Out-of-Competition*: Ecdysterone
赛内和**赛外**：蜕皮甾酮

2. Peptides Hormones, Growth Factors, Related Substances, and Mimetics:
肽类激素、生长因子、相关物质和模拟物：
In and *Out-of-Competition*: Gonadotrophin-releasing hormone (GnRH) analogues in females under 18 years only.
赛内和**赛外**：促性腺激素释放激素（GnRH）类似物，**仅适用于**18周岁以下女性。

3.Hypoxen (polyhydroxyphenylene thiosulfonate sodium):
Hypoxen（聚二羟基苯亚基硫代磺酸钠）：
In and *Out-of-Competition*
赛内和**赛外**

4.Stimulants:
刺激剂：
In-Competition only: Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine.
仅赛内：丁胺苯丙酮、咖啡因、尼古丁、去氧肾上腺素、苯丙氨醇、哌苯甲醇和昔奈福林。

5.Narcotics:
麻醉剂：
In-Competition only: Dihydrocodeine and tapentadol.
仅赛内：二氢可待因和他喷他多。

6.GLP-1 Agonists:
胰高血糖素样肽-1激动剂：
In and *Out-of-Competition:* Semaglutide and tirzepatide
赛内和**赛外**：**司美格鲁肽和替尔泊肽**

* The World Anti-Doping Code (Article 4.5) states: "*WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect potential patterns of misuse in sport.*"

*《世界反兴奋剂条例》（第4.5条）规定：“WADA应当与各签约方和政府协商，针对那些尚未列入《禁用清单》但WADA希望监控的物质建立监控程序，以便发现其在体育运动中潜在的滥用方式。”

Summary of Major Modifications and Explanatory Notes 2027 Prohibited List

2027年《禁用清单》主要修订及注释概要

Introduction - Substances of Abuse

引言-滥用物质

- The wording was changed to clarify that the presence of metabolites for Substances of Abuse should be taken into consideration in the results management process when relevant.
- 对措辞进行了修改，以澄清在结果管理过程中，如相关，应考虑滥用物质代谢物的存在。

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

所有场合禁用的物质和方法（赛内和赛外）

PROHIBITED SUBSTANCES

禁用物质

S0. Non-approved substances

未获批准的物质

- Many peptides, not approved for human use by regulatory authorities, fulfill the criteria of the World Anti-Doping Code for inclusion on the Prohibited List and fall under the S0 (Non-Approved Substances) class, or other classes (such as S2 or S4). Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health. In this regard, for clarity, peptides are now named as examples in this section.
- 许多尚未获得监管机构批准用于人体用途的肽类物质，符合《世界反兴奋剂条例》关于列入禁用清单的标准，列为S0类（未批准物质）或其他类别（如 S2 或 S4）。
- 即使某一个肽类物质未在清单中明确列出，仍须格外谨慎，因其仍可能被禁止使用，且可能对健康有害。为此，为明确起见，本节现以示例形式列出相关肽类物质的名称。

S4. Hormone and Metabolic Modulators

激素及代谢调节剂

- The title of section S4.2 was expanded to reflect current terminology for substances in this class.
- S4.2节的标题已予以扩展，以体现该类物质现行术语规范。

- Imlunestrant was added as an example in section S4.2.
- 新增依仑司群，在S4.2节中作为示例。
- Seladelpar was added as an example of PPAR-delta agonist.
- 新增司拉德帕，作为PPAR -δ 激动剂的示例。
- SLU-PP-332 and SLU-PP-915 were added as examples of metabolic modulators acting particularly on oxidative metabolism.
- 新增SLU-PP-332与SLU-PP-915，作为主要作用于氧化代谢的代谢调节剂的示例。

S5. Diuretics and Masking Agents
利尿剂与掩蔽剂
- Eplerenone and finerenone were added as examples.
- 新增依普利酮和非奈利酮作为示例。

SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION
赛内禁用的物质和方法

PROHIBITED SUBSTANCES
禁用物质

S8. Cannabinoids
大麻（酚）类
- The changes were made to reflect current scientific knowledge on the delta-9- tetrahydrocannabinol (Δ^9-THC) like-effects of commonly encountered cannabinoids.
- 本次修订旨在反映关于常见大麻素类物质所具有的Δ^9-四氢大麻酚类似效应的最新科学认知。
- Cannabidiol is not prohibited. However, cannabidiol extracted from cannabis plants may also contain varying concentrations of THC, which remains a prohibited substance.
- 大麻二酚本身并未被禁用。但从大麻植物中提取的大麻二酚可能还含有不同浓度的四氢大麻酚（THC），而该物质仍属禁用物质。

S9. Glucocorticoids
糖皮质激素
- Vaginal administration was added as a permitted route.
- 阴道给药已被列为允许的给药途径之一。

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS
特定体育项目中禁用的物质

P1. Beta-Blockers
β -阻断剂
- To be consistent with other federations in this section, the reference

to “all disciplines” was removed from WCBS.

- 为与本节中其他单项体育联合会的表述保持一致，已从世界台球运动联盟（WCBS）的相关条款中删除了“所有分项”的表述。

MONITORING PROGRAM
监控程序

• The following substances were removed as sufficient information has been collected:
已经收集到足够信息，以下物质被移除：
- codeine;
可待因；
- dermorphin and its analogues;
皮啡肽及其类似物；
- hydrocodone and
氢可酮；
- fentanyl and tramadol Out-of-Competition.
赛外的芬太尼和曲马多。

*For further information on previous modifications and clarifications, please consult the *Prohibited List* Frequently Asked Questions at https://www.wada-ama.org/en/prohibited-list#faq-anchor.
*如需了解之前有关修订和澄清的更多信息，请参阅《禁用清单》常见问题：https://www.wada-ama.org/en/prohibited-list#faq-anchor

信息公开选项：依申请公开